Alzheimer’s disease (AD) is a complex and heterogeneous condition requiring early detection and intervention. Biomarkers contribute to diagnostic processes and real-world evidence (RWE) outcomes. Robust real-world data can drive insights to bridge disease, policy, clinical trials, and access gaps in the diagnosis and treatment of AD, providing valuable objective endpoints.

PurpleLab®, a leading health tech company specializing in real-world data and medical claims insights, and Payerset, the industry leader in enterprise price transparency data, announced today a strategic partnership to launch a trusted price intelligence solution suite, setting a new standard in healthcare intelligence.  This collaboration empowers healthcare organizations with unparalleled accuracy and actionable insights,…

Enhance clinical trial development with PurpleLab’s data-driven insights. ​ Access patient-level data, optimize trial design, improve recruitment, and generate real-world evidence.

Launching a new pharmaceutical product is a high-stakes endeavor, with nearly 40% of launches failing to meet expectations. To improve these odds, companies must shift to a data-driven approach, leveraging real-world insights to engage decision-makers effectively across the patient journey.

This case study explores how a pharmaceutical company successfully planned and executed a Phase III clinical trial for a new oncology drug.

Authored by Lauren Kushner, Head of Healthcare at MiQ, and Ted Sweetser, VP of Advertising Partnerships and Strategy at PurpleLab. 2024 was a year of considerable change for the pharmaceutical industry. The biggest trend was undoubtedly the progression of the Inflation Reduction Act’s negotiated drug pricing, which sees CMS negotiating on pricing for a published…

Healthcare advertisers and their marketing partners face challenges that other direct to consumer advertisers may not necessarily be confronted with. Namely, the ever-evolving world of privacy regulation and the requirements enacted by the federal and state governments with the goal of helping preserve patient anonymity.

Identifying high-volume prescribers and engaging with key opinion leaders (KOLs) in a target therapeutic area can be a challenge. In a new webinar, sponsored by PurpleLab, experts explore how PurpleLab’s data solutions can help foster a deeper understanding of physician prescribing behavior.

When evaluating a data partner, make sure you are choosing a trusted data partner that meets all your needs. This handy dandy checklist can help ensure that you’re selecting a trusted data partner.